ATE256117T1 - Neue umsetzungsbedingungen für die spaltung von silylethern bei der herstellung von paclitaxel (taxol(r)) und paclitaxel -analogen - Google Patents

Neue umsetzungsbedingungen für die spaltung von silylethern bei der herstellung von paclitaxel (taxol(r)) und paclitaxel -analogen

Info

Publication number
ATE256117T1
ATE256117T1 AT00932151T AT00932151T ATE256117T1 AT E256117 T1 ATE256117 T1 AT E256117T1 AT 00932151 T AT00932151 T AT 00932151T AT 00932151 T AT00932151 T AT 00932151T AT E256117 T1 ATE256117 T1 AT E256117T1
Authority
AT
Austria
Prior art keywords
paclitaxel
cleavage
analogues
taxane
silyl ethers
Prior art date
Application number
AT00932151T
Other languages
English (en)
Inventor
Ambarish Singh
Raymond E Weaver Jr
Gerald L Powers
Victor W Rosso
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE256117T1 publication Critical patent/ATE256117T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
AT00932151T 1999-05-17 2000-05-08 Neue umsetzungsbedingungen für die spaltung von silylethern bei der herstellung von paclitaxel (taxol(r)) und paclitaxel -analogen ATE256117T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13446999P 1999-05-17 1999-05-17
PCT/US2000/012469 WO2000069840A1 (en) 1999-05-17 2000-05-08 Novel reaction conditions for the cleavage of silyl ethers in the preparation of paclitaxel (taxol®) and paclitaxel analogues

Publications (1)

Publication Number Publication Date
ATE256117T1 true ATE256117T1 (de) 2003-12-15

Family

ID=22463532

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00932151T ATE256117T1 (de) 1999-05-17 2000-05-08 Neue umsetzungsbedingungen für die spaltung von silylethern bei der herstellung von paclitaxel (taxol(r)) und paclitaxel -analogen

Country Status (17)

Country Link
US (1) US6184395B1 (de)
EP (1) EP1178979B1 (de)
JP (1) JP2002544269A (de)
KR (1) KR100648125B1 (de)
AT (1) ATE256117T1 (de)
AU (1) AU761389B2 (de)
CA (1) CA2373819A1 (de)
DE (1) DE60007115T2 (de)
DK (1) DK1178979T3 (de)
ES (1) ES2211550T3 (de)
HK (1) HK1042302B (de)
HU (1) HUP0201176A3 (de)
IL (1) IL144976A0 (de)
MX (1) MXPA01011046A (de)
PT (1) PT1178979E (de)
TW (1) TWI257387B (de)
WO (1) WO2000069840A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6916942B2 (en) * 2000-02-03 2005-07-12 Bristol-Myers Squibb Company Process for the preparation of C-4 carbonate taxanes
US6750246B1 (en) 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
WO2003045953A1 (fr) * 2001-11-29 2003-06-05 Daiichi Pharmaceutical Co., Ltd. Cristaux de derive de taxane et procede de production associe
RS52904A (en) * 2001-12-20 2006-12-15 Bristol-Myers Squib Company Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
US7605278B2 (en) 2002-08-04 2009-10-20 Natural Pharmaceuticals, Inc. Methods and compositions for converting taxane amides to paclitaxel or other taxanes
US8703982B2 (en) 2003-03-17 2014-04-22 Phyton Holdings Llc Purification of taxanes
JP4499383B2 (ja) * 2003-07-11 2010-07-07 良明 木曽 水溶性プロドラッグ
FR2859996B1 (fr) * 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
FR2882362B1 (fr) * 2005-02-23 2007-05-11 Seripharm Procede de preparation du paclitaxel
CA2723654A1 (en) * 2008-05-07 2009-11-12 Ivax Research, Llc Processes for preparation of taxanes and intermediates thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601676B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
USRE34277E (en) 1988-04-06 1993-06-08 Centre National De La Recherche Scientifique Process for preparing taxol
FR2629818B1 (fr) * 1988-04-06 1990-11-16 Centre Nat Rech Scient Procede de preparation du taxol
FR2687150B1 (fr) * 1992-02-07 1995-04-28 Rhone Poulenc Rorer Sa Procede de preparation de derives du taxane.
FR2702212B1 (fr) 1993-03-02 1995-04-07 Rhone Poulenc Rorer Sa Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
TW467896B (en) 1993-03-19 2001-12-11 Bristol Myers Squibb Co Novel β-lactams, methods for the preparation of taxanes and sidechain-bearing taxanes
FR2718135B1 (fr) * 1994-04-05 1996-04-26 Rhone Poulenc Rorer Sa Procédé de préparation d'hydroxy-7 taxanes.
WO1999054322A1 (en) * 1998-04-20 1999-10-28 Lolita Zamir The semi-synthesis of baccatin iii

Also Published As

Publication number Publication date
EP1178979A1 (de) 2002-02-13
EP1178979A4 (de) 2002-06-12
MXPA01011046A (es) 2002-07-22
IL144976A0 (en) 2002-06-30
TWI257387B (en) 2006-07-01
DE60007115T2 (de) 2004-09-02
PT1178979E (pt) 2004-04-30
AU761389B2 (en) 2003-06-05
EP1178979B1 (de) 2003-12-10
CA2373819A1 (en) 2000-11-23
HK1042302A1 (en) 2003-12-19
WO2000069840A1 (en) 2000-11-23
ES2211550T3 (es) 2004-07-16
JP2002544269A (ja) 2002-12-24
KR100648125B1 (ko) 2006-11-24
HK1042302B (zh) 2004-10-08
US6184395B1 (en) 2001-02-06
DK1178979T3 (da) 2004-03-22
HUP0201176A3 (en) 2005-02-28
AU4992000A (en) 2000-12-05
DE60007115D1 (de) 2004-01-22
KR20010112493A (ko) 2001-12-20
HUP0201176A2 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
ATE256117T1 (de) Neue umsetzungsbedingungen für die spaltung von silylethern bei der herstellung von paclitaxel (taxol(r)) und paclitaxel -analogen
RO110491B1 (ro) Procedeu pentru prepararea unor derivati de taxol
DE69433188T2 (de) Beta-Lactam, Verfahren zur Herstellung Taxane-Derivate und Taxane mit Seitenketten
WO2003097656A3 (en) Novel substituted sulfamate anticonvulsant derivatives
TW200633977A (en) Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives
MX2007004157A (es) Procedimiento de semisintesis para la preparacion de 10-desacetil-n-debenzoil-paclitaxel.
CN100569749C (zh) 4－羰基－（s）－脯氨酸衍生物的制备方法
EP2867202B1 (de) Verfahren zur herstellung einer stereoselektiven epoxyketonverbindung
EP1785416A3 (de) 9, 10-Alpha, Alpha-OH-Taxan-Analogen und Herstellungsverfahren dafür
AU731651B2 (en) Method for acylating 10-deacetylbaccatin III selectively at the C-10 position
NO20011634L (no) Krystall av diuridintetrafosfat eller salter derav, og fremgangsmåte for fremstilling av samme og fremgangsmåte forfremstilling av nevnte forbindelse
DE50104094D1 (de) Verfahren zur Herstellung von reinem Triethylendiamin (TEDA)
CA2148943A1 (en) Oxidation of glycoside substituted taxanes to taxol or taxol precursors and new taxane compounds formed as intermediates
WO2003087070A3 (en) Growth hormone secretagogues
WO2008111563A1 (ja) 鉄サラン錯体触媒を用いた光学活性スルホキシド化合物の製造法
EP1810968A3 (de) 9, 10-a, a-OH-Taxan-Analoge und Herstellungsverfahren dafür
US20100029957A1 (en) Semi-Synthetic Process for the Preparation of Taxane Derivatives
CN108997454B (zh) 一种β-熊果苷的化学合成方法
ATE384730T1 (de) Verfahren zur herstellung von palladium(0)- haltigen verbindungen
KR20010043230A (ko) Ｃ-7, ｃ-10 디-ｃｂｚ 박카틴 ｉｉｉ로부터 파클리탁셀을제조하는 방법 및 이를 제조하는데 사용하기 위한 중간체
HUP0402020A2 (hu) Eljárás 14béta-hidroxi-bakkatin III 1,14-karbonát előállítására
CN101823991A (zh) 一种合成偕二过氧化合物的方法
CN104356156B (zh) 一种四元环紫杉烷侧链化合物的制备方法
HUP0302407A2 (hu) Új eljárás (S)-N-terc-butil-1,2,3,4-tetrahidroizokinolin-3-karboxamid előállítására és az eljárás intermedierjei
JP2004123588A (ja) メバロラクトンの製造方法

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1178979

Country of ref document: EP

REN Ceased due to non-payment of the annual fee